Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + ixazomib
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Combination therapy of carboplatin and ixazomib. Carboplatin is an organoplatinum antineoplastic alkylating agent used in various cancer treatments. Ixazomib is a proteasome inhibitor that blocks the ability of cancer cells to reuse certain proteins. The combination is being investigated for efficacy in metastatic triple-negative breast cancer (TNBC) and potentially other cancer types.
02
Targets
DNAPSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on carboplatin + ixazomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + ixazomib.